Trex Company Announces CEO Succession Plan

Trex Company Announces CEO Succession Plan

Bryan Fairbanks to Retire After Nearly 23 Years with TREX; Adam Zambanini Appointed President and Chief Executive Officer

WINCHESTER, Va.–(BUSINESS WIRE)–
Trex Company, Inc. (NYSE:TREX), the world’s largest manufacturer of high-performance, low-maintenance composite decking and railing products, today announced that Bryan H. Fairbanks, Trex’s President and Chief Executive Officer, will retire from Trex after nearly 23 years with the Company, effective April 28, 2026. The Board of Directors has appointed Adam D. Zambanini, Trex’s current Executive Vice President and Chief Operating Officer, as Trex’s next President and Chief Executive Officer and as a member of the Board, effective April 28, 2026. Following the transition period, Mr. Fairbanks will serve as an outside consultant to the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224152104/en/

Bryan H. Fairbanks to Retire After Nearly 23 Years with Trex.

Bryan H. Fairbanks to Retire After Nearly 23 Years with Trex.

Mr. Zambanini brings more than 20 years of leadership experience at Trex, most recently serving as Executive Vice President and Chief Operating Officer. Over the course of his tenure, he has held multiple leadership positions, including President of Residential Products and Vice President of Marketing, and has been instrumental in driving Trex’s market growth, product development and operational execution.

James Cline, Chairman of the Board of Directors, said “Bryan has made an immeasurable mark on the organization and embodies Trex’s core qualities – vision, innovation and discipline. In determining a successor, the Board undertook a comprehensive evaluation process, including assessing both internal and external candidates, and Adam was the clear and most capable successor to Bryan. He is a strong leader and brand-builder and his knowledge of Trex’s business, product roadmap, markets and people is unmatched. Adam has been a true partner to Bryan in developing our strategic initiatives and product innovation, which will be an important advantage as he steps into his new role.”

Mr. Zambanini, said, “It is an honor to succeed Bryan, someone who has made an impact on me and so many across Trex. As I assume the role as the Company’s next CEO, I am energized by the opportunity to partner with our dynamic leaders and continue to drive growth and shareholder value. Trex is the undisputed leader in wood-alternative decking and railing and I am confident that Trex will continue to win in our markets and categories, while building on our strong financial profile.”

“After a nearly 23-year career at Trex, including the past six years as CEO, now is the right time to transition leadership to Adam as part of our succession plan,” said Mr. Fairbanks. “I have had the opportunity to work with the best talent in our industry and lead our iconic Trex brand that has shaped the decking industry and delivered above market returns for our investors. Having worked closely with Adam for two decades, I have been impressed with his leadership capabilities and his drive for performance. I take pride in what we have built and move on with confidence in Trex’s future.”

Mr. Cline concluded, “Six years ago, Bryan was announced as CEO and during his tenure he has grown Trex, shown resilience within a challenging industry environment, strategically invested to enhance the Company’s future position and built a world-class team of innovators and operators that have consistently delivered for our channel partners and consumers. On behalf of the Board and the Trex team, we owe Bryan our deepest appreciation and thank him for his continued support to ensure this is a seamless transition for all stakeholders.”

Fourth Quarter and Full Year 2025 Earnings Results

In a separate press release issued today, Trex announced its fourth quarter and full year 2025 financial results. The Company will hold a conference call today, Tuesday, February 24, 2026, at 4:30 p.m. ET.

About Adam Zambanini

Mr. Zambanini has served as our Executive Vice President and Chief Operating Officer since October 25, 2023. He previously served as President of Trex Residential Products between July 2018 and October 2023. Mr. Zambanini served as Vice President, Marketing between January 2011 and July 2018, and he served in a number of other roles at the Company between September 2005 and December 2010. Prior to joining Trex, Mr. Zambanini held marketing and market development roles at Rubbermaid Commercial Products, where he most recently served as Product Manager, and began his professional career as a project engineer at Flambeau Inc. Mr. Zambanini received a Bachelor of Science degree in mechanical engineering from Penn State University and a Master of Business Administration degree from Averett University.

About Trex Company, Inc.

For more than 30 years, Trex Company [NYSE: TREX] has invented, reinvented, and defined the composite decking category. Today, the company is the world’s #1 brand of sustainably made, wood-alternative decking and railing, and a leader in high-performance, low-maintenance outdoor living products. Boasting the industry’s strongest distribution network, Trex sells products through more than 6,700 retail outlets across six continents. Through strategic licensing agreements, the company offers a comprehensive outdoor living portfolio that includes deck drainage, flashing tapes, deck lighting, outdoor kitchen components, fencing, pergolas, spiral stairs, lattice, cornhole and outdoor furniture – all marketed under the Trex® brand. Based in Winchester, Va., Trex is proud to have been named America’s Most Trusted® Outdoor Decking^ for the past 6 years (2021-2026). The company also holds a place on Barron’s list of the 100 Most Sustainable U.S. Companies (2024 and 2025), was named one of America’s Most Responsible Companies by Newsweek, ranked as one of the 100 Best ESG Companies by Investor’s Business Daily, and named the Sustainable Brand Leader in the decking category by Green Builder Media for the 15th consecutive year. For more information, visit Trex.com. You may also follow Trex on Facebook (trexcompany), Instagram (trexcompany), X (Trex_Company), LinkedIn (trex-company), TikTok (trexcompany), Pinterest (trexcompany) and Houzz (trex-company-inc), or view product and demonstration videos on the brand’s YouTube channel (TheTrexCo).

^2021-2026 DISCLAIMER: Trex received the highest numerical score in the proprietary Lifestory Research 2021-2026 America’s Most Trusted® Outdoor Decking studies. Study results are based on the experiences and perceptions of people surveyed. Your experiences may vary. Visit www.lifestoryresearch.com.

Forward-Looking Statements

Statements contained in this press release that state the Company’s or its management’s expectations or predictions of the future are forward-looking statements intended to be covered by the safe harbor provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934. The forward-looking statements in this press release include expectations with respect to executive transition dates, among other items. It is important to note that actual results could differ materially from those projected in such forward-looking statements based on numerous factors, including those outside of the Company’s control. For more information concerning factors that could cause actual results to differ from those expressed or forecasted, see the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q, and other reports filed with the Securities and Exchange Commission.

Lynn Morgen/Casey Kotary

ADVISIRY Partners

212-750-5800

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Banking Architecture Professional Services Residential Building & Real Estate Commercial Building & Real Estate Construction & Property Other Manufacturing Chemicals/Plastics Building Systems Finance Landscape Manufacturing

MEDIA:

Photo
Photo
Bryan H. Fairbanks to Retire After Nearly 23 Years with Trex.
Photo
Photo
Adam D. Zambanini Appointed President and Chief Executive Officer.
Logo
Logo

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

Event: TD Cowen 46th Annual Health Care Conference – Boston

Date: Tuesday, March 3, 2026
Presentation and Fireside Time: 3:10 pm ET

Event: Leerink Global Healthcare Conference – Miami

Date: Monday, March 9, 2026
Fireside Time: 8:40 am ET

Event: Jefferies Biotech on the Beach Summit – Miami

Date: Tuesday, March 10, 2026

Members of the Spyre management team will host one-on-one investor meetings during the conferences.

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre’s website at www.spyre.com.

For Investors:     
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
[email protected]



Kilroy Realty Corporation Declares Quarterly Dividend

Kilroy Realty Corporation Declares Quarterly Dividend

LOS ANGELES–(BUSINESS WIRE)–
Kilroy Realty Corporation (NYSE: KRC) (“Kilroy” or the “Company”) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.54 per common share payable on April 8, 2026 to stockholders of record on March 31, 2026. The dividend is equivalent to an annual rate of $2.16 per share.

About Kilroy Realty Corporation

Kilroy is a leading U.S. landlord and developer, with operations in the San Francisco Bay Area, Los Angeles, Seattle, San Diego, and Austin. The Company has earned global recognition for sustainability, building operations, innovation, and design. As a pioneer and innovator in the creation of a more sustainable real estate industry, the Company’s approach to modern business environments helps drive creativity and productivity for some of the world’s leading technology, media, life science, and business services companies.

The Company is a publicly traded real estate investment trust (“REIT”) and member of the S&P MidCap 400 Index with more than seven decades of experience developing, acquiring, and managing office, life science, and mixed-use projects.

As of December 31, 2025, Kilroy’s stabilized portfolio totaled approximately 16.3 million square feet of primarily office and life science space that was 81.6% occupied and 83.8% leased. The Company also had approximately 1,000 residential units in Hollywood and San Diego, which had a quarterly average occupancy of 94.1%. In addition, the Company had one development project in the tenant improvement phase totaling approximately 872,000 square feet with a total estimated investment of $1.2 billion.

A Leader in Sustainability and Commitment to Corporate Social Responsibility

Kilroy has a longstanding commitment to sustainability and continues to be a recognized leader in our sector. For over a decade, the Company and its sustainability initiatives have been recognized with numerous honors, including earning the GRESB five star rating and being named a sector and regional leader in the Americas. Other honors have included the Nareit Leader in the Light Award, being listed on the Dow Jones Sustainability World Index, being named ENERGY STAR Partner of the Year, and receiving the ENERGY STAR highest honor of Sustained Excellence.

Kilroy is proud to have achieved carbon neutral operations across our portfolio since 2020. The Company also has a longstanding commitment to maintain high levels of LEED, Fitwell, and ENERGY STAR certifications across the portfolio.

Kilroy is committed to cultivating a company culture that makes a positive difference in our employees’ lives by focusing on development, celebrating our unique backgrounds, promoting employee health and wellness, and dedicating ourselves to being a responsible corporate citizen through our community service and philanthropic efforts.

More information is available at http://www.kilroyrealty.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs, and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends, and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results, and events may vary materially from those indicated or implied in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results, or events. Numerous factors could cause actual future performance, results, and events to differ materially from those indicated in the forward-looking statements, including, among others: global market and general economic conditions, including actual and potential tariffs and periods of heightened inflation, and their effect on our liquidity and financial conditions and those of our tenants; adverse economic or real estate conditions generally, and specifically, in the States of California, Texas, and Washington; risks associated with our investment in real estate assets, which are illiquid, and with trends in the real estate industry; defaults on or non-renewal of leases by tenants; any significant downturn in tenants’ businesses, including bankruptcy, lack of liquidity or lack of funding, and the impact labor disruptions or strikes, such as episodic strikes in the media industry, may have on our tenants’ businesses; our ability to re-lease property at or above current market rates; reduced demand for office space, including as a result of remote working and flexible working arrangements that allow work from remote locations other than an employer’s office premises; costs to comply with government regulations, including environmental remediation; the availability of cash for distribution and debt service, and exposure to risk of default under debt obligations; increases in interest rates and our ability to manage interest rate exposure; changes in interest rates and the availability of financing on attractive terms or at all, which may adversely impact our future interest expense and our ability to pursue development, redevelopment, and acquisition opportunities and refinance existing debt; a decline in real estate asset valuations, which may limit our ability to dispose of assets at attractive prices, or obtain or maintain debt financing, and which may result in write-offs or impairment charges; significant competition, which may decrease the occupancy and rental rates of properties; potential losses that may not be covered by insurance; the ability to successfully complete acquisitions and dispositions on announced terms; the ability to successfully operate acquired, developed, and redeveloped properties; the ability to successfully complete development and redevelopment projects on schedule and within budgeted amounts; delays or refusals in obtaining all necessary zoning, land use, and other required entitlements, governmental permits and authorizations for our development and redevelopment properties; increases in anticipated capital expenditures, tenant improvement, and/or leasing costs; defaults on leases for land on which some of our properties are located; adverse changes to, or enactment or implementations of, tax laws or other applicable laws, regulations, or legislation, as well as business and consumer reactions to such changes; risks associated with joint venture investments, including our lack of sole decision-making authority, our reliance on co-venturers’ financial condition, and disputes between us and our co-venturers; environmental uncertainties and risks related to natural disasters; risks associated with climate change and our sustainability strategies, and our ability to achieve our sustainability goals; and our ability to maintain our status as a REIT. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the dates on which they are made. We assume no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information, or otherwise, except to the extent we are required to do so in connection with our ongoing requirements under federal securities laws.

Doug Bettisworth

Vice President, Corporate Finance

(310) 481-8585

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property Building Systems REIT

MEDIA:

Logo
Logo

Aktis Oncology to Present at Upcoming March Investor Conferences

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026.

TD Cowen 46

th

Annual Health Care Conference

Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ET
Location: Boston, MA

Leerink Partners Global Healthcare Conference

Date & Time: Monday, March 9, 2026, at 1:40 p.m. ET
Location: Miami, FL

A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

About Aktis’ Radioconjugate Platform

Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Aktis’ therapeutic miniprotein radioconjugates are designed to maximize anti-cancer activity through high penetration, internalization and retention in cancer cells, while quickly clearing from normal organs and tissues. The Aktis platform further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Leveraging this platform, Aktis is advancing a pipeline of next-generation targeted radiopharmaceuticals to address the unmet needs of patients across a broad spectrum of solid tumors.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most-advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.

Media Contact:

Melone Communications, LLC
Liz Melone
617-256-6622
[email protected]

Investor Contact:

Precision AQ
Alex Lobo
212-698-8802
[email protected]



Finance of America Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call on March 10, 2025

Finance of America Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call on March 10, 2025

PLANO, Texas–(BUSINESS WIRE)–Finance of America Companies Inc. (“Finance of America” or the “Company”) (NYSE: FOA),a leading provider of home equity-based financing solutions for a modern retirement, today announced that it will release results for the fourth quarter and full year ended December 31, 2025 after market closing on Tuesday, March 10, 2026.

Webcast and Earnings Conference Call

Management will host a webcast and conference call on the same day at 5:00 pm Eastern Time to discuss the Company’s results for the fourth quarter and full year ended December 31, 2025. A copy of the press release and investor presentation will be posted prior to the call under the “Investors” section on Finance of America’s website at https://ir.financeofamericacompanies.com/.

To listen to the audio webcast of the conference call, please visit the “Investors” section of the Company’s website at https://ir.financeofamericacompanies.com/. The conference call can also be accessed by dialing the following:

  • 1-800-715-9871 (Domestic)

  • 1-646-307-1963 (International)

  • Conference ID: 5706924

Replay

A replay of the call will also be available on the Company’s website approximately two hours after the conclusion of the conference call until March 24, 2026. To access the replay, dial 1-800-770-2030 (United States) or 1-609-800-9909 (International). The replay pin number is 5706924. The replay can also be accessed on the “Investors” section of the Company’s website at https://ir.financeofamericacompanies.com/.

About Finance of America Companies

Finance of America (NYSE: FOA) is a leading provider of home equity-based financing solutions for a modern retirement. In addition, Finance of America offers capital markets and portfolio management capabilities primarily to optimize the distribution of its originated loans to investors. Finance of America is headquartered in Plano, Texas. For more information, please visit www.financeofamericacompanies.com.

For Finance of America Media Relations: [email protected]

For Finance of America Investor Relations: [email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Personal Finance Finance Professional Services Residential Building & Real Estate Construction & Property

MEDIA:

Logo
Logo

Appian Corporation to Present at the Morgan Stanley Technology, Media & Telecom Conference

MCLEAN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) — Appian (NASDAQ: APPN), today announced that Serge Tanjga, Chief Financial Officer, will present at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco, CA. The fireside chat is scheduled for Monday, March 2, 2026 at 12:20pm Pacific Time and will be webcast live at the following link: https://cc.webcasts.com/

Replays of the fireside chat will be available for a limited time under the “News and Events” section of the Company’s investor relations website at http://investors.appian.com.

About Appian

Appian provides process automation technology. We automate complex processes in large enterprises and governments. Our platform is known for its unique reliability and scale. We’ve been automating processes for 25 years and understand enterprise operations like no one else. For more information, visit appian.com. [Nasdaq: APPN]

Investor Contact


[email protected]

Media Contact

Valerie Verlander
Senior Manager, Media Relations North America
[email protected]



BlueLinx Announces Fourth Quarter and Full Year 2025 Results

BlueLinx Announces Fourth Quarter and Full Year 2025 Results

ATLANTA–(BUSINESS WIRE)–
BlueLinx Holdings Inc. (NYSE: BXC), a leading U.S. wholesale distributor of building products, today reported financial results for the fiscal three months and twelve months ended January 3, 2026.

FOURTH QUARTER 2025 HIGHLIGHTS

  • Net sales of $716 million

  • Gross profit of $113 million, gross margin of 15.7% and specialty gross margin of 18.1%

  • Net loss of $(8.6) million, or $(1.08) loss per share

  • Adjusted net loss of $(3.7) million, or $(0.47) adjusted loss per share

  • Adjusted EBITDA of $14 million

  • Free cash flow of $56 million

FULL YEAR 2025 HIGHLIGHTS

  • Net sales of $3.0 billion

  • Gross profit of $452 million, gross margin of 15.3%, and specialty gross margin of 18.0%

  • Net income of $0.2 million, or $0.02 diluted earnings per share

  • Adjusted net income of $8 million, or $0.97 adjusted diluted earnings per share

  • Adjusted EBITDA of $83 million

  • Free cash flow of $33 million

  • Available liquidity of $726 million, including $386 million cash/cash equivalents on hand

  • Completion of $38 million in share repurchases

“Our fourth quarter and full year 2025 results demonstrated our ability to grow the business across multiple product lines and in key customer channels, despite persistent challenging market conditions,” said Shyam Reddy, President and CEO of BlueLinx. “The results were highlighted by increased sales, higher volumes and solid margin performance in a tough housing market, which clearly shows our ability to gain share and generate positive results when driving targeted sales efforts through a focused profitable growth strategy. Our key customer channel focus, product strategy, and enhanced value-add services make us more essential to our customers and suppliers.”

“Specialty products margins significantly improved from the third quarter of 2025 to a gross margin of 18.1%. Structural products gross margins also improved sequentially to 10.0% for the quarter,” said Kelly Wall, Senior Vice President, Chief Financial Officer and Treasurer of BlueLinx. “During the fourth quarter, we generated $56 million in free cash flow primarily due to our effective inventory management. With strong liquidity and minimal net debt, we remain well-positioned to execute on our strategic investments.”

FOURTH QUARTER 2025 FINANCIAL PERFORMANCE

In the fourth quarter of fiscal 2025, which consisted of 14 weeks compared to 13 weeks for the prior year period, net sales were $716 million, an increase of $5.2 million, or 0.7% when compared to the fourth quarter of fiscal 2024. Gross profit was $113 million, a decrease of $0.7 million, or 0.6%, year-over-year, and gross margin was 15.7%, down 20 basis points from the prior year period.

As previously disclosed, on October 31, 2025, we acquired Disdero Lumber Co., LLC (“Disdero”), an Oregon-based distributor of high-end specialty building products. The financial results of Disdero are included in our consolidated results beginning November 1, 2025.

Net sales of specialty products, which includes products such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products, increased $21.1 million, or 4.2%, to $505 million. This increase was primarily due to volume gains in most categories and the addition of Disdero, partially offset by price deflation driven by continued challenging external market conditions. Gross profit from specialty product sales was $91.6 million, an increase of $2.8 million, or 3.2%, compared to the fourth quarter last year. Gross margin was 18.1% compared to 18.4% in the prior year period.

Net sales of structural products, which includes products such as lumber, plywood, oriented strand board, rebar, and remesh, decreased $15.9 million, or 7.0%, to $211 million in the fourth quarter of fiscal 2025, and gross profit from sales of structural products decreased $3.6 million to $21.0 million in the quarter. The decreases in structural sales and gross profit were due primarily to price declines in lumber and panels, partially offset by volume growth. Compared to fourth quarter 2024, average composite pricing for lumber decreased 12% and panel prices decreased 20%. Gross margin on structural product sales was 10.0% in the fourth quarter, down from 10.8% in the prior year period.

Selling, general and administrative (“SG&A”) expenses were $102.5 million in the fourth quarter of fiscal 2025, an increase of $9.9 million from $92.6 million for the fourth quarter of fiscal 2024. The year-over-year increase was due primarily to higher personnel expenses, the addition of Disdero, the extra week in the fourth quarter of fiscal 2025, and increased sales and logistics expenses driven by our strategic channel growth, including multi-family.

Other operating expenses, net in the current fiscal quarter were primarily acquisition-related and other non-recurring expenses.

Net loss for the current fiscal quarter was $(8.6) million, or $(1.08) loss per share, versus net income of $5.3 million, or $0.63 per diluted share, in the prior year quarter. The net loss was primarily driven by higher SG&A expenses, higher depreciation and amortization expense from asset additions, and acquisition-related transactions costs. Adjusted net loss for the current fourth quarter was $(3.7) million, or $(0.47) loss per share.

Adjusted EBITDA was $13.9 million, or 1.9% of net sales, compared to $21.5 million, or 3.0% of net sales in the prior year period.

Net cash generated from operating activities was $61.8 million in the fourth quarter of fiscal 2025 compared to $18.7 million in the prior year period. The increase in cash generated from operating activities was due primarily by positive changes in working capital driven by more effective inventory management, partially offset by the cash impact of lower net income in the quarter. We used $5.4 million of cash primarily for improvements to our distribution facilities and for our digital transformation initiative, a multi-year initiative aimed at modernizing and integrating our core technologies by improving data quality, strengthening operational systems, and digitizing key processes. We also entered into $3.3 million of new finance leases mainly to update our fleet during the current quarter.

FULL YEAR 2025 FINANCIAL PERFORMANCE

For fiscal year 2025, which consisted of 53 weeks compared to 52 weeks for the prior fiscal year, net sales were $3.0 billion, a slight increase of $1.5 million year-over-year, reflecting an increase of $7.1 million, or 0.3%, for specialty product net sales, partially offset by a slight decline of $5.6 million, or 0.6%, for structural product net sales. Gross profit was $451.6 million, a decrease of $37.5 million, or 7.7% year-over-year, and gross margin was 15.3%, down 130 basis points from 16.6%. Gross profit for full year 2024 included a net benefit of $12.7 million for import duty-related items; such amounts were not material for full year 2025. Excluding this benefit, gross margin would have been 16.1% for full year 2024. The duty items were related to changes in retroactive rates for anti-dumping duties and to classification adjustments for certain goods imported by the Company.

Net sales of specialty products increased $7.1 million, or 0.3% to $2.1 billion in fiscal year 2025. The overall increase in specialty product net sales was due to volume growth in some categories and the addition of Disdero, partially offset by price deflation. Gross profit from specialty product sales was $369.0 million in the current year, a decrease of $28.6 million, or 7.2%, year-over-year and gross margin in the current year was 18.0% compared to 19.4% in the prior year. The prior year included the aforementioned net benefit of $12.7 million for import duty-related items from prior periods. Excluding this benefit, gross margin for specialty products would have been 18.8% for the prior fiscal year.

Net sales of structural products decreased $5.6 million, or 0.6%, to $901.0 million in fiscal year 2025, and gross profit from sales of structural products decreased $8.9 million to $82.6 million. The decreases in structural products net sales and gross profit were due primarily to market-based price deflation in panels, partially offset by pricing and slight volume growth for lumber. Compared to fiscal year 2024, average composite pricing for lumber in the U.S. increased while panel prices significantly decreased. Gross margin on structural product sales was 9.2% compared to 10.1% for the prior fiscal year.

SG&A expenses were $381.1 million during fiscal year 2025, up $15.6 million, or 4.3%, compared to the prior fiscal year. The year-over-year increase was due to the addition of Disdero, the extra week in fiscal year 2025, increased sales and logistics expenses driven by our strategic channel growth, including multi-family, as well as continuing technology initiatives associated with our digital transformation.

Other operating expenses, net in the current fiscal year were primarily acquisition-related and other non-recurring expenses, partially offset by insurance recoveries received in 2025 related to property damaged at our Erwin, Tennessee facility due to Hurricane Helene in late 2024.

Net income was $0.2 million, or $0.02 per diluted share, versus $53.1 million, or $6.19 per diluted share in the prior fiscal year. Fiscal year 2024 reflects the aforementioned $12.7 million net benefit for import-duty related items. Adjusted net income was $7.8 million and adjusted diluted earnings per share was $0.97 in the current fiscal year, compared to $55.2 million or adjusted diluted earnings per share of $6.44 in the prior fiscal year.

Adjusted EBITDA in fiscal year 2025 was $82.6 million, or 2.8% of net sales, compared to $131.4 million, or 4.4% of net sales in fiscal year 2024.

Net cash generated from operating activities was $59.8 million for fiscal year 2025 compared to $85.2 million in fiscal year 2024. This decrease in cash provided by operating activities during fiscal year 2025 was primarily due to lower cash impact of net income in the year, partially offset by positive changes in working capital driven by more effective inventory management. Free cash flow was $32.9 million in fiscal year 2025 compared to $45.1 million in the prior fiscal year.

CAPITAL ALLOCATION AND FINANCIAL POSITION

During fiscal year 2025, we invested $26.9 million to property and equipment, primarily for improvements to our distribution facilities and for our digital transformation initiative, compared to $40.1 million in fiscal year 2024. We also entered into $44.6 million of new finance leases, mainly to update our fleet, in the current fiscal year compared to $19.4 million in the prior fiscal year. We did not repurchase any of our common stock during the fourth quarter of fiscal 2025, but repurchased $37.7 million in fiscal year 2025. At quarter-end, we had $8.7 million remaining under our $100 million authorization announced in October 2023 and an additional $50 million from our more recent authorization announced in July 2025, for a total of $58.7 million available for share repurchases.

As of January 3, 2026, total debt outstanding was $621 million, including $300 million of senior secured notes that mature in 2029 and $321 million of finance leases. Available liquidity was $726 million which included an undrawn revolving credit facility that had $340 million of availability plus cash and cash equivalents of $386 million. Net debt was $(5) million, which consisted of total debt and finance lease obligations, less real property finance lease obligations of $241 million, and less cash and cash equivalents of $386 million, resulting in a net leverage ratio of (0.1x) using a trailing twelve-month Adjusted EBITDA of $83 million.

FIRST QUARTER 2026 OUTLOOK

Based on the first seven weeks of the first quarter of fiscal 2026, we are expecting specialty product gross margin to be in the range of 17% to 18%, and structural product gross margin to be in the range of 9% to 10%. We also expect average daily sales volumes to be lower than in the fourth quarter of 2025 due to normal seasonal patterns and severe winter weather, but higher than the weather‑impacted first quarter of 2025.

CONFERENCE CALL INFORMATION

BlueLinx will host a conference call on February 25, 2026, at 10:00 a.m. Eastern Time, accompanied by a supporting slide presentation.

A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of the BlueLinx website at https://investors.bluelinxco.com, and a replay of the webcast will be available at the same site shortly after the webcast is complete.

To participate in the live teleconference:

Domestic Live: 1-888-660-6392

Passcode: 9140086

To listen to a replay of the teleconference, which will be available through March 4, 2026:

Domestic Replay: 1-800-770-2030

Passcode: 9140086

ABOUT BLUELINX

BlueLinx (NYSE: BXC) is a leading U.S. wholesale distributor of residential and commercial building products with both branded and private-label SKUs across product categories such as lumber, panels, engineered wood, siding, millwork, and industrial products. With a strong market position, broad geographic coverage footprint servicing 50 states, and the strength of a locally focused sales force, we distribute a comprehensive range of products to our customers which include national home centers, pro dealers, cooperatives, specialty distributors, regional and local dealers and industrial manufacturers. BlueLinx provides a wide range of value-added services and solutions to our customers and suppliers, and we operate our business through a broad network of distribution centers. To learn more about BlueLinx, please visit www.bluelinxco.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. Forward-looking statements include, without limitation, any statement that predicts, forecasts, indicates or implies future results, performance, liquidity levels or achievements, and may contain the words “believe,” “anticipate,” “could,” “expect,” “estimate,” “intend,” “may,” “project,” “plan,” “should,” “will,” “will be,” “will likely continue,” “will likely result,” “would,” or words or phrases of similar meaning.

The forward-looking statements in this press release include statements about our strategy, liquidity, and debt, our long-run positioning relative to industry conditions, future share repurchases, and the information set forth under the heading “First Quarter 2026 Outlook”.

Forward-looking statements in this press release are based on estimates and assumptions made by our management that, although believed by us to be reasonable, are inherently uncertain. Forward-looking statements involve risks and uncertainties that may cause our business, strategy, or actual results to differ materially from the forward-looking statements. These risks and uncertainties include those discussed in greater detail in our filings with the Securities and Exchange Commission. We operate in a changing environment in which new risks can emerge from time to time. It is not possible for management to predict all of these risks, nor can it assess the extent to which any factor, or a combination of factors, may cause our business, strategy, or actual results to differ materially from those contained in forward-looking statements. Factors that may cause these differences include, among other things: adverse housing market conditions; consolidation among competitors, suppliers, and customers; disintermediation risk; our dependence on international suppliers and manufacturers for certain products and related exposure to risks of new or increased tariffs, changes in trade policies, and other risks that could affect our financial condition; pricing and product cost variability; volumes of product sold; competition; the cyclical nature of the industry in which we operate; loss of products or key suppliers and manufacturers; information technology security risks and business interruption risks; effective inventory management relative to our sales volume or the prices of the products we produce; the ability to attract, train, and retain highly qualified associates and other key personnel while controlling related labor costs; acquisitions and the integration and completion of such acquisitions; business disruptions; exposure to product liability and other claims and legal proceedings related to our business and the products we distribute; the impacts of climate change; successful implementation of our strategy; wage increases or work stoppages by our union employees; costs imposed by federal, state, local, and other regulations; compliance costs associated with federal, state, and local environmental protection laws; the effects of epidemics, global pandemics or other widespread public health crises and governmental rules and regulations; fluctuations in our operating results; our level of indebtedness and our ability to incur additional debt to fund future needs; changes in insurance-related deductible/retention liabilities based on actual loss development experience; the covenants of the instruments governing our indebtedness limiting the discretion of our management in operating the business; the potential to incur more debt; the fact that we have consummated certain sale leaseback transactions with resulting long-term non-cancelable leases, many of which are or will be finance leases; the fact that we lease many of our distribution centers, and we would still be obligated under these leases even if we close a leased distribution center; inability to raise funds necessary to finance a required repurchase of our senior secured notes; a lowering or withdrawal of debt ratings; changes in our product mix; increases in fuel and other energy prices or availability of third-party freight providers; the possibility that the value of our deferred tax assets could become impaired; changes in our expected annual effective tax rate could be volatile; the costs and liabilities related to our participation in multi-employer pension plans could increase; the risk that our cash flows and capital resources may be insufficient to service our existing or future indebtedness; interest rate risk, which could cause our debt service obligations to increase; potential to incur impairment charges if we determine that our goodwill has become impaired; and changes in, or interpretation of, accounting principles.

Given these risks and uncertainties, we caution you not to place undue reliance on forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law.

NON-GAAP MEASURES AND SUPPLEMENTAL FINANCIAL INFORMATION

The Company reports its financial results in accordance with GAAP. The Company also believes that presentation of certain non-GAAP measures may be useful to investors and may provide a more complete understanding of the factors and trends affecting the business than using reported GAAP results alone. Any non-GAAP measures used herein are reconciled to their most directly comparable GAAP measures herein in the “Reconciliation of Non-GAAP Measurements” table later in this release. The Company cautions that non-GAAP measures are not intended to present superior measures of our financial condition from those measures determined under GAAP and should be considered in addition to, but not as a substitute for, the Company’s reported GAAP results. The Company further cautions that its non-GAAP measures, as used herein, are not necessarily comparable to other similarly titled measures of other companies due to differences in methods of calculation.

Adjusted EBITDA and Adjusted EBITDA Margin. BlueLinx defines Adjusted EBITDA as an amount equal to net income (loss) plus interest expense and all interest expense related items, income taxes, depreciation and amortization, and further adjusted for certain non-cash items and other special items, including compensation expense from share based compensation, one-time charges associated with the legal, consulting, and professional fees related to our merger and acquisition activities, gains or losses on sales of properties, amortization of deferred gains on real estate, and expense associated with our restructuring activities, such as severance, in addition to other significant and/or one-time, nonrecurring, non-operating items.

The Company presents Adjusted EBITDA because it is a primary measure used by management to evaluate operating performance. Management believes this metric helps to enhance investors’ overall understanding of the financial performance and cash flows of the business. Management also believes Adjusted EBITDA is helpful in highlighting operating trends. Adjusted EBITDA is frequently used by securities analysts, investors, and other interested parties in their evaluation of companies, many of which present an Adjusted EBITDA measure when reporting their results.

We determine our Adjusted EBITDA Margin, which we sometimes refer to as our Adjusted EBITDA as a percentage of net sales, by dividing our Adjusted EBITDA for the applicable period by our net sales for the applicable period. We believe that this ratio is useful to investors because it more clearly defines the quality of earnings and operational efficiency of translating sales to profitability.

Adjusted Net Income (Loss) and Adjusted Earnings (Loss) Per Share. BlueLinx defines Adjusted Net Income (Loss) as Net Income or Loss adjusted for certain non-cash items and other special items, including compensation expense from share based compensation, one-time charges associated with the legal, consulting, and professional fees related to our merger and acquisition activities, gains or losses on sales of properties, realization of deferred gains on real estate, and expense associated with our restructuring activities, such as severance, in addition to other significant and/or one-time, nonrecurring, non-operating items, further adjusted for the tax impacts of such reconciling items. BlueLinx defines Adjusted Earnings (Loss) Per Share (basic and/or diluted) as the Adjusted Net Income (Loss) for the period divided by the weighted average outstanding shares (basic and/or diluted) for the periods presented. However, for any period with an Adjusted Net Loss, only Adjusted Basic Loss Per Share is presented for the period. We believe that Adjusted Net Income (Loss) and Adjusted Earnings (Loss) Per Share (basic and/or diluted) are useful to investors to enhance investors’ overall understanding of the financial performance of the business. Management also believes Adjusted Net Income (Loss) and Adjusted Earnings (Loss) Per Share (basic and/or diluted) are helpful in highlighting operating trends.

Our Adjusted Net Income (Loss) and Adjusted Earnings (Loss) Per Share (basic and/or diluted) are not presentations made in accordance with GAAP and are not intended to present superior measures of our financial condition from those measures determined under GAAP. Adjusted Net Income (Loss) and Adjusted Earnings (Loss) Per Share (basic or diluted), as used herein, are not necessarily comparable to other similarly titled captions of other companies due to differences in methods of calculation. These non-GAAP measures are reconciled in the “Reconciliation of Non-GAAP Measurements” table later in this release.

Free Cash Flow. BlueLinx defines free cash flow as net cash provided by operating activities less total capital expenditures. Free cash flow is a measure used by management to assess our financial performance, and we believe it is useful for investors because it relates the operating cash flow of the Company to the capital that is spent to continue and improve business operations. In particular, free cash flow indicates the amount of cash generated after capital expenditures that can be used for, among other things, investment in our business, strengthening our balance sheet, and repayment of our debt obligations. Free cash flow does not represent the residual cash flow available for discretionary expenditures since there may be other nondiscretionary expenditures that are not deducted from the measure. Free cash flow is not a presentation made in accordance with GAAP and is not intended to present a superior measure of financial condition from those determined under GAAP. Free cash flow, as used herein, is not necessarily comparable to other similarly titled captions of other companies due to differences in methods of calculation. This non-GAAP measure is reconciled in the “Reconciliation of Non-GAAP Measurements” table later in this release.

Net Debt, Net Debt Excluding Real Property Finance Lease Liabilities, Overall Net Leverage Ratio, and Net Leverage Ratio Excluding Real Property Finance Lease Liabilities. BlueLinx calculates Net Debt as its total short- and long-term debt, including outstanding balances under our term loan and revolving credit facility and the total amount of its obligations under finance leases, less cash and cash equivalents. Net Debt Excluding Real Property Finance Lease Liabilities is calculated in the same manner as Net Debt, except the total amount of obligations under real estate finance leases are excluded. Although our credit agreements do not contain leverage covenants, a net leverage ratio excluding finance lease obligations for real property is included within the terms of our revolving credit agreement. We believe that Net Debt and Net Debt Excluding Real Property Finance Lease Liabilities are useful to investors because our management reviews both metrics as part of its management of overall liquidity, financial flexibility, capital structure and leverage, and creditors and credit analysts monitor our net debt as part of their assessments of our business. We determine our Overall Net Leverage Ratio by dividing our Net Debt by Twelve-Month Trailing Adjusted EBITDA. Our calculation of Net Leverage Ratio Excluding Real Property Finance Lease Liabilities is determined by dividing our Net Debt Excluding Real Property Finance Lease Liabilities by Twelve-Month Trailing Adjusted EBITDA. We believe that these ratios are useful to investors because they are indicators of our ability to meet our future financial obligations. In addition, our Net Leverage Ratio is a measure that is frequently used by investors and creditors. Our Net Debt, Net Debt Excluding Real Property Finance Lease Liabilities, Overall Net Leverage Ratio, and Net Leverage Ratio Excluding Real Property Finance Lease Liabilities are not made in accordance with GAAP and are not intended to present a superior measure of our financial condition from measures and ratios determined under GAAP. The calculations of our Net Debt, Net Debt Excluding Real Property Finance Lease Liabilities, Overall Net Leverage Ratio, and Net Leverage Ratio Excluding Real Property Finance Lease Liabilities are presented in the table on the last page of this Exhibit 99.1. Net Debt, Net Debt Excluding Real Property Finance Lease Liabilities, Overall Net Leverage Ratio, and Net Leverage Ratio Excluding Real Property Finance Lease Liabilities, as used herein, are not necessarily comparable to other similarly titled captions of other companies due to differences in methods of calculation.

BLUELINX HOLDINGS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

Fiscal Quarter Ended

 

Fiscal Year Ended

 

January 3, 2026

 

December 28, 2024

 

January 3, 2026

 

December 28, 2024

 

(14 weeks)

 

(13 weeks)

 

(53 weeks)

 

(52 weeks)

(In thousands, except per share amounts)

 

 

 

 

 

 

 

Net sales

$

715,804

 

 

$

710,637

 

 

$

2,954,007

 

 

$

2,952,532

 

Cost of products sold

 

603,181

 

 

 

597,292

 

 

 

2,502,379

 

 

 

2,463,393

 

Gross profit

 

112,623

 

 

 

113,345

 

 

 

451,628

 

 

 

489,139

 

Gross margin percentage

 

15.7

%

 

 

15.9

%

 

 

15.3

%

 

 

16.6

%

Operating expenses (income):

 

 

 

 

 

 

 

Selling, general, and administrative

 

102,470

 

 

 

92,619

 

 

 

381,109

 

 

 

365,532

 

Depreciation and amortization

 

10,819

 

 

 

9,405

 

 

 

39,905

 

 

 

38,488

 

Recognition of deferred gains on real estate

 

(983

)

 

 

(982

)

 

 

(3,934

)

 

 

(3,934

)

Gain from sale of properties, net

 

 

 

 

 

 

 

 

 

 

(272

)

Other operating expenses, net

 

3,559

 

 

 

273

 

 

 

2,065

 

 

 

1,755

 

Total operating expenses

 

115,865

 

 

 

101,315

 

 

 

419,145

 

 

 

401,569

 

Operating income

 

(3,242

)

 

 

12,030

 

 

 

32,483

 

 

 

87,570

 

Non-operating expenses:

 

 

 

 

 

 

 

Interest expense, net

 

8,714

 

 

 

5,320

 

 

 

32,354

 

 

 

19,364

 

Settlement of defined benefit pension plan

 

 

 

 

(255

)

 

 

 

 

 

(2,481

)

(Loss) income before (benefit) provision for income taxes

 

(11,956

)

 

 

6,965

 

 

 

129

 

 

 

70,687

 

(Benefit) provision for income taxes

 

(3,405

)

 

 

1,693

 

 

 

(90

)

 

 

17,571

 

Net (loss) income

$

(8,551

)

 

$

5,272

 

 

$

219

 

 

$

53,116

 

 

 

 

 

 

 

 

 

Basic (loss) earnings per share

$

(1.08

)

 

$

0.63

 

 

$

0.02

 

 

$

6.22

 

Diluted earnings per share

 

 

$

0.62

 

 

$

0.02

 

 

$

6.19

 

BLUELINX HOLDINGS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

 

As of

 

January 3, 2026

 

December 28, 2024

(In thousands, except share data)

 

ASSETS

Current assets:

 

 

 

Cash and cash equivalents

$

385,843

 

$

505,622

Accounts receivable, net

 

218,161

 

 

225,837

Inventories, net

 

325,998

 

 

355,909

Other current assets

 

54,466

 

 

46,620

Total current assets

 

984,468

 

 

1,133,988

Property and equipment, net

 

286,760

 

 

249,556

Operating lease right-of-use assets

 

54,608

 

 

47,221

Goodwill

 

67,226

 

 

55,372

Intangible assets, net

 

86,700

 

 

26,881

Deferred income tax asset, net

 

50,615

 

 

50,578

Other non-current assets

 

18,902

 

 

14,121

Total assets

$

1,549,279

 

$

1,577,717

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

 

 

 

Accounts payable

$

136,388

 

$

170,202

Accrued compensation

 

17,466

 

 

16,706

Finance lease liabilities – current

 

22,348

 

 

12,541

Operating lease liabilities – current

 

8,969

 

 

8,478

Real estate deferred gains – current

 

3,935

 

 

3,935

Other current liabilities

 

22,173

 

 

21,862

Total current liabilities

 

211,279

 

 

233,724

Non-current liabilities:

 

 

 

Long-term debt

 

296,660

 

 

295,061

Finance lease liabilities – less current portion

 

298,931

 

 

280,002

Operating lease liabilities – less current portion

 

47,075

 

 

40,114

Real estate deferred gains – less current portion

 

59,362

 

 

63,296

Other non-current liabilities

 

18,657

 

 

19,079

Total liabilities

 

931,964

 

 

931,276

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY:

Preferred Stock, $0.01 par value, 30,000,000 shares authorized, none outstanding

 

 

 

Common Stock, $0.01 par value, 20,000,000 shares authorized, 7,866,497 and 8,650,046 outstanding, respectively

 

79

 

 

83

Additional paid-in capital

 

94,762

 

 

124,103

Retained earnings

 

522,474

 

 

522,255

Total stockholders’ equity

 

617,315

 

 

646,441

 

 

 

 

Total liabilities and stockholders’ equity

$

1,549,279

 

$

1,577,717

BLUELINX HOLDINGS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

Fiscal Quarter Ended

 

Fiscal Year Ended

 

January 3, 2026

 

December 28, 2024

 

January 3, 2026

 

December 28, 2024

 

(14 weeks)

 

(13 weeks)

 

(53 weeks)

 

(52 weeks)

(In thousands)

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Net (loss) income

$

(8,551

)

 

$

5,272

 

 

$

219

 

 

$

53,116

 

Adjustments to reconcile net (loss) income to cash provided by operations:

 

 

 

 

 

 

 

Depreciation and amortization

 

10,819

 

 

 

9,405

 

 

 

39,905

 

 

 

38,488

 

Amortization of debt discount and issuance costs

 

375

 

 

 

328

 

 

 

1,510

 

 

 

1,318

 

Gains from sale of property

 

 

 

 

 

 

 

 

 

 

(272

)

Insurance recoveries in excess of carrying values of property & equipment

 

 

 

 

 

 

 

(2,443

)

 

 

 

Recognition of deferred gains from real estate

 

(983

)

 

 

(982

)

 

 

(3,934

)

 

 

(3,934

)

Share-based compensation

 

2,937

 

 

 

808

 

 

 

11,252

 

 

 

7,749

 

(Benefit) provision for deferred income taxes

 

(2,229

)

 

 

728

 

 

 

(36

)

 

 

2,678

 

Changes in operating assets and liabilities, net of business combination:

 

 

 

 

 

 

 

Accounts receivable

 

56,868

 

 

 

52,212

 

 

 

14,053

 

 

 

2,573

 

Inventories

 

35,929

 

 

 

(15,368

)

 

 

45,959

 

 

 

(12,271

)

Accounts payable

 

(33,159

)

 

 

(14,930

)

 

 

(36,009

)

 

 

13,002

 

Other current assets

 

1,875

 

 

 

(10,120

)

 

 

(3,710

)

 

 

(20,012

)

Other assets and liabilities

 

(2,047

)

 

 

(8,609

)

 

 

(6,982

)

 

 

2,743

 

Net cash provided by operating activities

 

61,834

 

 

 

18,744

 

 

 

59,784

 

 

 

85,178

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Acquisition of business, net of cash acquired

 

(95,210

)

 

 

 

 

 

(95,210

)

 

 

 

Proceeds from sales of property and insurance recoveries

 

31

 

 

 

60

 

 

 

2,656

 

 

 

899

 

Property and equipment investments

 

(5,447

)

 

 

(20,279

)

 

 

(26,933

)

 

 

(40,109

)

Net cash used in investing activities

 

(100,626

)

 

 

(20,219

)

 

 

(119,487

)

 

 

(39,210

)

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Common stock repurchases

 

 

 

 

(15,315

)

 

 

(38,126

)

 

 

(45,297

)

Debt financing costs

 

(483

)

 

 

 

 

 

(3,095

)

 

 

 

Repurchase of shares to satisfy employee tax withholdings

 

(93

)

 

 

(108

)

 

 

(2,538

)

 

 

(3,365

)

Principal payments on finance lease liabilities

 

(4,149

)

 

 

(3,761

)

 

 

(16,317

)

 

 

(13,427

)

Net cash used in financing activities

 

(4,725

)

 

 

(19,184

)

 

 

(60,076

)

 

 

(62,089

)

Net change in cash and cash equivalents

 

(43,517

)

 

 

(20,659

)

 

 

(119,779

)

 

 

(16,121

)

Cash and cash equivalents at beginning of period

 

429,360

 

 

 

526,281

 

 

 

505,622

 

 

 

521,743

 

Cash and cash equivalents at end of period

$

385,843

 

 

$

505,622

 

 

$

385,843

 

 

$

505,622

 

The following schedule presents our revenues disaggregated by specialty and structural product category:

 

 

Fiscal Quarter Ended

 

Fiscal Year Ended

 

January 3, 2026

 

December 28, 2024

 

January 3, 2026

 

December 28, 2024

 

(14 weeks)

 

(13 weeks)

 

(53 weeks)

 

(52 weeks)

(Dollar amounts in thousands)

 

 

 

 

 

 

 

Net sales:

 

 

 

 

 

 

 

Specialty products

$

504,689

 

 

$

483,610

 

 

$

2,052,990

 

 

$

2,045,910

 

Structural products

 

211,115

 

 

 

227,027

 

 

 

901,017

 

 

 

906,622

 

Total

$

715,804

 

 

$

710,637

 

 

$

2,954,007

 

 

$

2,952,532

 

 

 

 

 

 

 

 

 

Gross profit:

 

 

 

 

 

 

 

Specialty products

$

91,583

 

 

$

88,747

 

 

$

368,993

 

 

$

397,625

 

Structural products

 

21,040

 

 

 

24,598

 

 

 

82,635

 

 

 

91,514

 

Total

$

112,623

 

 

$

113,345

 

 

$

451,628

 

 

$

489,139

 

 

 

 

 

 

 

 

 

Gross margin % :

 

 

 

 

 

 

 

Specialty products

 

18.1

%

 

 

18.4

%

 

 

18.0

%

 

 

19.4

%

Structural products

 

10.0

%

 

 

10.8

%

 

 

9.2

%

 

 

10.1

%

Company gross margin

 

15.7

%

 

 

15.9

%

 

 

15.3

%

 

 

16.6

%

BLUELINX HOLDINGS INC.

RECONCILIATION OF NON-GAAP MEASUREMENTS

(Unaudited)

 

The following table reconciles Net (loss) income to Adjusted EBITDA (non-GAAP) for the periods indicated:

 

 

Fiscal Quarter Ended

 

Fiscal Year Ended

 

January 3, 2026

 

December 28, 2024

 

January 3, 2026

 

December 28, 2024

 

(14 weeks)

 

(13 weeks)

 

(53 weeks)

 

(52 weeks)

(In thousands)

 

Net (loss) income

$

(8,551

)

 

$

5,272

 

 

$

219

 

 

$

53,116

 

Adjustments:

 

 

 

 

 

 

 

Depreciation and amortization

 

10,819

 

 

 

9,405

 

 

 

39,905

 

 

 

38,488

 

Interest expense, net

 

8,714

 

 

 

5,320

 

 

 

32,354

 

 

 

19,364

 

(Benefit) provision for income taxes

 

(3,405

)

 

 

1,693

 

 

 

(90

)

 

 

17,571

 

Share-based compensation expense

 

2,937

 

 

 

808

 

 

 

11,252

 

 

 

7,749

 

Recognition of deferred gains on real estate

 

(983

)

 

 

(982

)

 

 

(3,934

)

 

 

(3,934

)

Gains from sales of property

 

 

 

 

 

 

 

 

 

 

(272

)

Pension settlement and withdrawal costs(1)

 

 

 

 

(255

)

 

 

 

 

 

(2,481

)

Inventory step-up adjustment

 

798

 

 

 

 

 

 

798

 

 

 

 

Acquisition-related costs(2)

 

2,074

 

 

 

 

 

 

2,537

 

 

 

 

Restructuring and other(3)

 

1,486

 

 

 

274

 

 

 

(472

)

 

 

1,755

 

Adjusted EBITDA

$

13,889

 

 

$

21,535

 

 

$

82,569

 

 

$

131,356

 

 

 

 

 

 

 

 

 

(1) Reflects expenses and related adjustments related to our previously disclosed settlement of the BlueLinx Corporation Hourly Retirement Defined Benefit Plan.

(2) Primarily reflects legal, professional, technology and other expenses for due diligence, acquisition, and post-acquisition integration activities.

(3) Reflects net losses from Hurricane Helene in fiscal 2024, related insurance recoveries in fiscal 2025, and non-recurring items.

The following table reconciles Net income (loss) and Diluted earnings (loss) per share to Adjusted net income (non-GAAP) and Adjusted diluted earnings per share (non-GAAP):

 

 

Fiscal Quarter Ended

 

Fiscal Year Ended

 

January 3, 2026

 

December 28, 2024

 

January 3, 2026

 

December 28, 2024

 

(14 weeks)

 

(13 weeks)

 

(53 weeks)

 

(52 weeks)

(In thousands, except per share data)

 

Net (loss) income

$

(8,551

)

 

$

5,272

 

 

$

219

 

 

$

53,116

 

Adjustments:

 

 

 

 

 

 

 

Share-based compensation expense

 

2,937

 

 

 

808

 

 

 

11,252

 

 

 

7,749

 

Recognition of deferred gains on real estate

 

(983

)

 

 

(982

)

 

 

(3,934

)

 

 

(3,934

)

Gain from sales of property

 

 

 

 

 

 

 

 

 

 

(272

)

Pension settlement and withdrawal costs(1)

 

 

 

 

(255

)

 

 

 

 

 

(2,481

)

Inventory step-up adjustment

 

798

 

 

 

 

 

 

798

 

 

 

 

Acquisition-related costs (2)

 

2,074

 

 

 

 

 

 

2,537

 

 

 

 

Restructuring and other (3)

 

1,486

 

 

 

274

 

 

 

(472

)

 

 

1,755

 

Tax impacts of reconciling items above (4)

 

(1,494

)

 

 

38

 

 

 

(2,555

)

 

 

(701

)

Adjusted net (loss) income – non-GAAP

$

(3,733

)

 

$

5,155

 

 

$

7,845

 

 

$

55,232

 

 

 

 

 

 

 

 

 

Basic (loss) earnings per share

$

(1.08

)

 

$

0.63

 

 

$

0.02

 

 

$

6.22

 

Diluted earnings per share

 

 

 

0.62

 

 

$

0.02

 

 

$

6.19

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding – Basic

 

7,865

 

 

 

8,356

 

 

 

7,984

 

 

 

8,531

 

Weighted average shares outstanding – Diluted

 

7,913

 

 

 

8,431

 

 

 

8,039

 

 

 

8,572

 

 

 

 

 

 

 

 

 

Adjusted basic EPS – non-GAAP

$

(0.47

)

 

$

0.61

 

 

$

0.98

 

 

$

6.47

 

Adjusted diluted EPS – non-GAAP

 

 

$

0.61

 

 

$

0.97

 

 

$

6.44

 

 

 

 

 

 

 

 

 

(4) Income tax impact calculated based on the effective income tax rate for the respective fiscal quarterly periods and fiscal year periods presented. However, for fiscal year 2025, a combined statutory rate for federal and state income taxes was applied.

In the following table, our Adjusted EBITDA margin (non-GAAP) is calculated and compared to Net income (loss) as a percentage of Net sales:

 

 

Fiscal Quarter Ended

 

Fiscal Year Ended

 

January 3, 2026

 

December 28, 2024

 

January 3, 2026

 

December 28, 2024

 

(14 weeks)

 

(13 weeks)

 

(53 weeks)

 

(52 weeks)

(Dollar amounts in thousands)

 

 

 

 

 

 

 

 

 

Net sales

$

715,804

 

 

$

710,637

 

 

$

2,954,007

 

 

$

2,952,532

 

Net (loss) income

 

(8,551

)

 

 

5,272

 

 

 

219

 

 

 

53,116

 

Net (loss) income as a percentage of Net sales

 

(1.2

)%

 

 

0.7

%

 

 

%

 

 

1.8

%

 

 

 

 

 

 

 

 

Net sales

$

715,804

 

 

$

710,637

 

 

$

2,954,007

 

 

$

2,952,532

 

Adjusted EBITDA – non-GAAP(1)

 

13,889

 

 

 

21,535

 

 

 

82,569

 

 

 

131,356

 

Adjusted EBITDA margin – non-GAAP

 

1.9

%

 

 

3.0

%

 

 

2.8

%

 

 

4.4

%

 
(1) See the table that reconciles Net (loss) income to Adjusted EBITDA (non-GAAP)

The following table shows the calculations of our “Net Debt,” “Net Leverage Ratio,” and our “Net Leverage Ratio Excluding Real Property Finance Lease Liabilities,” as those non-GAAP measures are used and presented within the terms of our revolving credit agreement.

 

 

As of

($ amounts in thousands)

January 3, 2026

 

December 28, 2024

Long term debt (1)

$

300,000

 

 

$

300,000

 

Finance lease liabilities for equipment and vehicles

 

80,635

 

 

 

49,785

 

Finance lease liabilities for real property

 

240,644

 

 

 

242,758

 

Total debt and finance leases

 

621,279

 

 

 

592,543

 

Less: available cash and cash equivalents

 

385,843

 

 

 

505,622

 

Net debt (non-GAAP)

$

235,436

 

 

$

86,921

 

 

 

 

 

Net Debt, excluding finance lease liabilities for real property

$

(5,208

)

 

$

(155,837

)

 

 

 

 

Twelve-month trailing adjusted EBITDA (see above reconciliations)

$

82,569

 

 

$

131,356

 

 

 

 

 

Net Leverage Ratio

2.9x

 

0.7x

Net Leverage Ratio Excluding Real Property Finance Lease Liabilities

(0.1x)

 

(1.2x)

 

(1) As of January 3, 2026 and December 28, 2024, our long-term debt is comprised of $300.0 million of senior-secured notes issued in October 2021. These notes are presented under the long-term debt caption of our consolidated balance sheet, and as of January 3, 2026 were $296.7 million which is net of unamortized debt discount of $2.0 million and unamortized debt issuance costs of $1.3 million. As of December 28, 2024, these notes were reported on our consolidated balance sheet at $295.1 million, which is net of unamortized discount of $2.5 million and unamortized debt issuance costs of $2.4 million. Our senior secured notes are presented in this table at their face value for the purposes of calculating our net leverage ratio.

The following schedule reconciles Net cash provided by operating activities to Free cash flow (non-GAAP):

 

 

Fiscal Quarter Ended

 

Fiscal Year Ended

 

January 3, 2026

 

December 28, 2024

 

January 3, 2026

 

December 28, 2024

 

(14 weeks)

 

(13 weeks)

 

(53 weeks)

 

(52 weeks)

(In thousands)

 

Net cash provided by operating activities

$

61,834

 

 

$

18,744

 

 

$

59,784

 

 

$

85,178

 

Less: property and equipment investments

 

(5,447

)

 

 

(20,279

)

 

 

(26,933

)

 

 

(40,109

)

Free cash flow – non-GAAP

$

56,387

 

 

$

(1,535

)

 

$

32,851

 

 

$

45,069

 

 

 

 

 

 

 

 

 

 

INVESTOR & MEDIA CONTACT

Tom Morabito

Investor Relations Officer

(470) 394-0099

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Architecture Commercial Building & Real Estate Construction & Property Natural Resources Other Manufacturing Manufacturing Forest Products Residential Building & Real Estate

MEDIA:

Logo
Logo

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET.

To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact: 
[email protected]
[email protected] 



Curbline Properties Announces 6% Increase in Common Stock Dividend

Curbline Properties Announces 6% Increase in Common Stock Dividend

NEW YORK–(BUSINESS WIRE)–
Curbline Properties Corp. (NYSE: CURB), an owner of convenience centers in suburban, high household income communities, declared today a first quarter 2026 dividend on its common stock of $0.17 per share, which represents a 6% increase from the fourth quarter 2025 dividend. The dividend is payable on April 8, 2026 to stockholders of record at the close of business on March 18, 2026.

About Curbline Properties

Curbline Properties is an owner and manager of convenience shopping centers positioned on the curbline of well-trafficked intersections and major vehicular corridors in suburban, high household income communities. The Company is a self-managed real estate investment trust (REIT) that is publicly traded under the ticker symbol “CURB” on the NYSE. Additional information about Curbline is available at curbline.com. To be included in the Company’s e-mail distributions for press releases and other investor news, please click here.

Safe Harbor

Curbline Properties Corp. considers portions of the information in this press release to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, both as amended, with respect to the Company’s expectation for future periods. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. For this purpose, any statements contained herein that are not historical fact, including statements regarding the Company’s projected operational and financial performance, strategy, prospects and plans, may be deemed to be forward-looking statements. There are a number of important factors that could cause our results to differ materially from those indicated by such forward-looking statements, including, among other factors, changes in the economic performance and value of the Company’s properties as a result of broad economic and local conditions, such as inflation, interest rate volatility and market reaction to tariffs and other trade policies; changes in local conditions such as an increase or decrease in the supply of, or demand for, retail real estate space in our geographic markets; the impact of changes in consumer trends, distribution channels, suburban population, retailing practices and the space needs of tenants; our dependence on rental income which depends on the successful operations and financial condition of tenants, the loss of which, including as a result of store closures or bankruptcy, could result in significant occupancy loss and negatively impact rental income from our properties; our ability to enter into new leases and renew existing leases, in each case, on favorable terms; our ability to identify, acquire, construct or develop additional properties that produce the cash flows that we expect and may be limited by competitive pressures, and our ability to manage our growth effectively and capture the efficiencies of scale that we expect from expansion; potential environmental liabilities; our ability to secure debt and equity financing on commercially acceptable terms or at all; the illiquidity of real estate investments which could limit our ability to make changes to our portfolio to respond to economic or other conditions; property damage, expenses related thereto and other business and economic consequences (including the potential loss of rental revenues) resulting from natural disasters, public health crises and weather-related factors in locations where we own properties, the ability to estimate accurately the amounts thereof and the sufficiency and timing of any insurance recovery payments related to such damages; any change in strategy; the effect of future offerings of debt and equity securities on the value of our common stock; any disruption, failure or breach of the networks or systems on which the Company relies, including as a result of cyber-attacks; impairment in the value of real estate property that we own; changes in tax laws impacting REITs and real estate in general, as well as our ability to maintain our REIT status; and our ability to retain and attract key management personnel. For additional factors that could cause the results of the Company to differ materially from those indicated in the forward-looking statements, please refer to the Company’s most recent Annual Report on Form 10-K under “Item 1A. Risk Factors” and our subsequent reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For additional information:

Conor Fennerty,

EVP and Chief Financial Officer

(216) 755-6200

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Discount/Variety Construction & Property Department Stores Office Products REIT Supermarket Convenience Store Home Goods Retail

MEDIA:

Logo
Logo

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

  • Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year.
  • Combined revenues of the Company’s four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™.
  • Cash, cash equivalents and current marketable securities were $308.7 million at December 31, 2025.
  • New patient initiation for ONAPGO resumed in the first quarter of 2026.
  • Full year 2026 guidance for total revenues of $840 million to $870 million, operating earnings of $0 million to $30 million, and adjusted operating earnings (Non-GAAP)(1) of $140 million to $170 million.

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year 2025 and associated Company developments.

“We made significant progress in 2025 against our strategic objectives, with record total revenues, including strong growth in combined revenues of our growth products, the successful acquisition of Sage Therapeutics, Inc., and the U.S. Food and Drug Administration’s approval and launch of ONAPGO for Parkinson’s disease,” said Jack Khattar, President and CEO of Supernus. “In 2026, we are focused on continued progress of our key growth products, including resumption of new patient initiation for ONAPGO, while advancing our pipeline of promising therapeutic candidates.”

Commercial Highlights

  • The Company has made progress securing additional product supply of ONAPGO from the current supplier and as a result has resumed new patient initiation. In addition, the Company is working with a second supplier, which is expected to begin supplying ONAPGO in 2027.
  • ONAPGO net product sales were $8.9 million in the fourth quarter of 2025 following the U.S. commercial launch in April 2025. Since launch, more than 1,800 enrollment forms have been submitted by over 540 prescribers.
  • Collaboration revenue from ZURZUVAE was $32.8 million in the fourth quarter of 2025. Collaboration revenue (ZURZUVAE) represents 50% of the net revenues for ZURZUVAE recorded by Biogen Inc. Fourth quarter 2025 U.S sales of ZURZUVAE, as reported by Biogen Inc., increased approximately 187% compared to the same period in 2024 and approximately 19% compared to the third quarter of 2025. The total number of prescriptions for ZURZUVAE increased by more than 150% in 2025 compared to 2024.
  • Net sales of Qelbree increased 9% to $81.0 million in the fourth quarter of 2025, compared to the same period in 2024, driven primarily by volume growth and partially offset by an annual gross-to-net deduction that was reflected in fourth quarter 2025. Total IQVIA prescriptions(5) for Qelbree were 253,742 for the fourth quarter 2025, representing an increase of 18% compared to the same period in the prior year.
  • Net sales of GOCOVRI increased 5% to $38.6 million in the fourth quarter of 2025, compared to the same period in 2024. Total number of prescriptions grew by 14% in 2025 compared to 2024.


Product Pipeline Update

SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy

  • The Phase 2b randomized, double-blind, placebo-controlled study of 3mg and 4mg twice daily doses is ongoing with a targeted enrollment of approximately 258 adult patients with treatment resistant focal seizures.

SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression

  • The Company initiated a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with major depressive disorder (MDD). The study will examine the safety and tolerability of SPN-820 2400 mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.

SPN-443 – Novel stimulant for attention-deficit/hyperactiv
ity disorder (ADHD)

  • The Company expects to initiate a Phase 1 single-ascending/multiple-ascending dose study in adult healthy volunteers in the second half of 2026.

Financial Highlights

This section includes information on non-GAAP financial measures. See “Non-GAAP Financial Information” section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release.


Revenues

The following table provides information regarding total revenues (dollars in millions):

    Three Months Ended

December 31,


    Years Ended

December 31,


 
      2025       2024     Change %     2025       2024     Change %
    (unaudited)         (unaudited)      
Net product sales                                
Qelbree   $ 81.0     $ 74.4     9 %   $ 304.7     $ 241.3     26 %
GOCOVRI     38.6       36.9     5 %     146.8       130.8     12 %
APOKYN®     9.6       20.1     (52 )%     47.8       73.9     (35 )%
Trokendi XR®     8.4       14.8     (43 )%     42.4       63.2     (33 )%
Oxtellar XR®     6.8       13.2     (48 )%     40.7       99.5     (59 )%
ONAPGO     8.9           100 %     17.3           100 %
Other(2)     4.8       7.0     (31 )%     26.9       29.0     (7 )%
Total net product sales     158.1       166.4     (5 )%     626.6       637.7     (2 )%
Collaboration revenue (ZURZUVAE)(3)     32.8           100 %     53.0           100 %
Royalty, licensing and other revenues(4)     20.7       7.8     165 %     39.4       24.1     63 %
Total revenues   $ 211.6     $ 174.2     21 %   $ 719.0     $ 661.8     9 %
                                 
Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP)(1)   $ 196.4     $ 146.2     34 %   $ 635.9     $ 499.1     27 %




Other Financial Highlights

  • The Company recognized $15.0 million of licensing revenue in the fourth quarter of 2025 related to the achievement of a regulatory milestone under its collaboration agreement with Shionogi.
  • Operating loss was $4.0 million and $62.3 million for the three and twelve months ended December 31, 2025, compared to operating earnings of $21.4 million and $81.7 million for the same periods in 2024. The change in both periods was primarily due to higher selling, general and administrative expenses, including approximately $72.9 million of acquisition-related costs associated with the Sage acquisition reported in 2025, change in contingent consideration loss (gain), and incremental intangible asset amortization expense for ZURZUVAE and ONAPGO intangible assets in 2025, partially offset by higher revenues.
  • Adjusted operating earnings (non-GAAP)(1) were $48.5 million and $158.7 million for the three and twelve months ended December 31, 2025, compared to $48.3 million and $183.7 million for the same periods in 2024.
  • Net loss and diluted loss per share were $4.1 million and $0.07 for the three months ended December 31, 2025, and $38.6 million and $0.68 for the twelve months December 31, 2025, respectively, compared to net earnings and diluted earnings per share of $15.3 million and $0.27 for the three months ended December 31, 2024, and $73.9 million and $1.32 for the twelve months December 31, 2024, respectively.
  • Cash, cash equivalents, and current marketable securities were approximately $308.7 million as of December 31, 2025, compared to $453.6 million as of December 31, 2024. This decrease was primarily due to the funding of the Sage acquisition, partially offset by cash generated from operations.

Full Year 2026 Financial Guidance

The Company expects to achieve the following financial objectives in 2026 (dollars in millions):

    Full Year 2026 Guidance

(as of February 24, 2026)
Total revenues include the following(6):
     ◦   ONAPGO net sales of $45 million – $70 million
     ◦   Trokendi XR and Oxtellar XR net sales of $40 – $50 million
  $840 – $870
Combined R&D and SG&A expenses   $620 – $650
Operating earnings   $0 – $30
Adjusted operating earnings (non-GAAP)(1)   $140 – $170



Non-GAAP Financial Information

This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. In addition to non-GAAP adjusted operating earnings, we also present total revenues excluding net sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants, we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company’s revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business.

There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include: non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies; these may not reflect all items of income and expense, as applicable, that affect our operations; there may be potential differences among calculation methodologies; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company’s 2026 financial guidance is also being provided on both a GAAP and a non-GAAP basis.

End Notes  
(1) See the section titled “Non-GAAP Financial Information” for information about this non-GAAP financial measure. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is included at the end of this press release.
(2) Includes net product sales of MYOBLOC®, XADAGO® and Osmolex ER®.
(3) Represents proportionate share of collaboration revenue from Biogen’s sales of ZURZUVAE to customers in the U.S. from July 31, 2025, the closing of the Sage acquisition.
(4) Royalty, licensing, and other revenues include royalties on generic Trokendi XR, Oxtellar XR, other licensed products and intellectual property.
(5) IQVIA data restatement July 1, 2025.
(6) Includes net product sales, collaboration revenue, and royalty, licensing, and other revenue.



Conference Call Details

Supernus will host a conference call and webcast today, February 24, 2026, at 4:30 p.m. Eastern Time to discuss these results. A live webcast will be available in the Events & Presentations section of the Company’s Investor Relations website www.supernus.com/investors.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s Investor Relations website www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.

For more information, please visit www.supernus.com.

Forward-Looking
Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management’s current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company’s ability to increase its net revenue from its products, and the products of its subsidiaries; the Company’s ability to commercialize its products, and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

Supernus Pharmaceuticals, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share data)

    December 31,   December 31,
      2025       2024  
         
Assets        
Current assets        
Cash and cash equivalents   $ 128,448     $ 69,331  
Marketable securities     180,222       384,281  
Accounts receivable, net     187,802       142,077  
Inventories, net     82,385       54,293  
Prepaid expenses and other current assets     65,325       36,088  
Total current assets     644,182       686,070  
Restricted cash     1,450        
Property and equipment, net     10,531       11,545  
Intangible assets, net     569,456       521,912  
Goodwill     124,882       117,019  
Deferred income tax assets, net     38,351        
Other assets     63,796       31,527  
Total assets   $ 1,452,648     $ 1,368,073  
         
Liabilities and stockholders’ equity        
Current liabilities        
Accounts payable and accrued liabilities   $ 107,800     $ 76,352  
Accrued product returns and rebates     161,097       168,705  
Contingent consideration, current portion     31,052       47,340  
Other current liabilities     38,222        
Total current liabilities     338,171       292,397  
Contingent consideration, long-term     206        
Operating lease liabilities, long-term     30,365       27,382  
Deferred income tax liabilities, net           4,961  
Other liabilities     22,192       7,600  
Total liabilities     390,934       332,340  
         
         
Stockholders’ equity        
Common stock, $0.001 par value; 130,000,000 shares authorized; 57,457,462 and 55,743,095 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively     57       56  
Additional paid-in capital     543,825       479,440  
Accumulated other comprehensive loss, net of tax     (44 )     (189 )
Retained earnings     517,876       556,426  
Total stockholders’ equity     1,061,714       1,035,733  
Total liabilities and stockholders’ equity   $ 1,452,648     $ 1,368,073  

Supernus Pharmaceuticals, Inc.

Consolidated Statements
of Ea
rnings (Loss)

(in thousands, except share and per shar
e data)

    Three Months Ended

December 31,


  Years Ended

December 31,
      2025       2024       2025       2024  
           
Revenues                  
Net product sales   $ 158,011     $ 166,395     $ 626,536     $ 637,696  
Collaboration revenue (ZURZUVAE)     32,832             52,996        
Royalty, licensing, and other revenues     20,729       7,764       39,420       24,121  
Total revenues     211,572       174,159       718,952       661,817  
                   
Costs and expenses                  
Cost of revenues(a)     23,007       26,098       74,562       77,906  
Research and development     27,827       28,647       106,235       108,796  
Selling, general and administrative     122,390       79,409       485,563       321,582  
Amortization of intangible assets     24,526       18,244       89,456       77,977  
Contingent consideration loss (gain)     17,759       356       25,419       (6,110 )
Total costs and expenses     215,509       152,754       781,235       580,151  
                   
Operating earnings (loss)     (3,937 )     21,405       (62,283 )     81,666  
                   
Other income (expense)                  
Interest and other income, net     2,023       4,977       13,253       16,204  
Total other income (expense), net     2,023       4,977       13,253       16,204  
                   
Earnings (loss) before income taxes     (1,914 )     26,382       (49,030 )     97,870  
                   
Income tax expense (benefit)     2,191       11,054       (10,480 )     24,005  
Net earnings (loss)   $ (4,105 )   $ 15,328     $ (38,550 )   $ 73,865  
                   
Earnings (Loss) per share                  
Basic   $ (0.07 )   $ 0.28     $ (0.68 )   $ 1.34  
Diluted   $ (0.07 )   $ 0.27     $ (0.68 )   $ 1.32  
                   
Weighted average shares outstanding                  
Basic     57,344,344       55,465,403       56,451,136       55,100,063  
Diluted     57,344,344       56,464,768       56,451,136       55,958,537  
________________________
(a) Excludes amortization of intangible assets.



Supernus Pharmaceuticals, Inc.


Reconciliations of GAAP to Non-GAAP Financial Information

(unaudited)

Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net sales

An itemized reconciliation between total revenues on a GAAP basis and Total revenues excluding Trokendi XR and Oxtellar XR net sales, a non-GAAP measure, is as follows (dollars in millions):

    Three Months Ended

December 31,
      Years Ended

December 31,
   
      2025       2024     Change %     2025       2024     Change %
Total revenues (GAAP)(a)   $ 211.6     $ 174.2     21 %   $ 719.0     $ 661.8     9 %
Adjustments:                        
Trokendi XR net product sales     (8.4 )     (14.8 )   (43 )%     (42.4 )     (63.2 )   (33 )%
Oxtellar XR net product sales     (6.8 )     (13.2 )   (48 )%     (40.7 )     (99.5 )   (59 )%
Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP)   $ 196.4     $ 146.2     34 %   $ 635.9     $ 499.1     27 %
___________________________________________
(a) Includes net product sales, collaboration revenue, and royalty, licensing, and other revenues.



Reconciliation of GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings

An itemized reconciliation between operating earnings (loss) on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions):

    Three Months Ended

December 31,


  Years Ended

December 31,
      2025       2024       2025       2024  
Operating earnings (loss) – As Reported (GAAP)   $ (4.0 )   $ 21.4     $ (62.3 )     81.7  
Adjustments:                  
Amortization of intangible assets     24.6       18.2       89.5       78.0  
Share-based compensation(a)(b)     9.7       7.7       56.0       27.8  
Contingent consideration loss (gain)     17.7       0.4       25.4       (6.1 )
Depreciation     0.5       0.6       2.1       2.4  
Other acquisition-related costs(b)                 48.0        
Operating earnings – As Adjusted (non-GAAP)   $ 48.5     $ 48.3     $ 158.7     $ 183.7  
_________________________________________
(a) Includes $2.1 million and $25.0 million of one-time compensation expense for the three and twelve months ended December 31, 2025, related to the acceleration of certain Sage equity awards in connection with the Sage Acquisition in July 2025 and certain awards granted to holders of the accelerated Sage equity awards which became probable of achievement in the fourth quarter of 2025.
(b) Total acquisition-related costs in connection with the Sage Acquisition, which includes the one-time other acquisition-related costs and the $2.1 million and $25.0 million compensation expense noted above, were $2.1 million and $72.9 million for the three months and twelve months ended December 31, 2025, respectively.


Non-GAAP adjusted operating earnings adjusts for one-time acquisition related costs and non-cash items, which include amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, and depreciation.

Reconciliation of Full Year 2026 Financial Guidance – GAAP Operating Earnings to Non-GAAP Adjusted Operating Earnings

An itemized reconciliation between projected operating earnings on a GAAP basis for the full year 2026 and projected adjusted operating earnings on a non-GAAP basis for the full year 2026 is as follows (dollars in millions):

    Full Year 2026 Guidance

(as of February 24, 2026)
Operating earnings – GAAP   $0 – $30
Adjustments:    
Amortization of intangible assets   $105
Share-based compensation   $35
Contingent consideration loss   $2
Depreciation   $3
Operating earnings – As Adjusted (non-GAAP)   $140 – $170



CONTACTS:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

or

INVESTOR CONTACT:

Peter Vozzo
ICR Healthcare
(443) 213-0505
[email protected]